Medium-chain-length polyhydroxyalkanoate depolymerase (PhaZ)

Medium-chain-length polyhydroxyalkanoate depolymerase, commonly known as mcl-PHA depolymerase or PhaZ, is an enzyme responsible for the hydrolytic degradation of medium-chain-length polyhydroxyalkanoates (mcl-PHAs) [3][10]. mcl-PHAs are polyesters accumulated by various bacteria, such as Pseudomonas and Streptomyces species, as intracellular carbon and energy storage materials [3][5]. The enzyme breaks down these polymers into monomers or oligomers, specifically (R)-3-hydroxyalkanoic acids, which the bacteria can then metabolize during periods of nutrient limitation [3][10]. Beyond its role in bacterial physiology, mcl-PHA depolymerase is of significant interest in the fields of environmental biotechnology and bioremediation for its ability to degrade biodegradable plastics [1][7]. In a medical context, research is exploring the enzyme's potential role in bacterial persistence and biofilm formation, which could make it a niche target for anti-virulence strategies against certain pathogens [10]. Furthermore, the enzyme's high substrate specificity and stereoselectivity are exploited for the production of chiral building blocks for the pharmaceutical industry [2][3]. Some studies utilize the enzyme's binding domain as a tool for targeted protein immobilization on PHA-based nanoparticles for drug delivery applications [11]. Currently, there are no approved drugs that target this enzyme, and it remains primarily a focus of industrial and fundamental microbiological research [1][3].

Other names

mcl-PHA depolymerasePoly(3-hydroxyalkanoate) depolymerasePhaZEC 3.1.1.76Polyhydroxyalkanoate depolymeraseMedium-chain-length poly depolymerase

No drugs are currently approved or in clinical development to target this enzyme; biologically, the enzyme catalyzes the hydrolysis of ester bonds in medium-chain-length polyhydroxyalkanoate polymers to release (R)-3-hydroxyalkanoate monomers for bacterial metabolism.